Amifostine (Ethyol®): Pharmacokinetic and Pharmacodynamic Effects in vivo

European Journal of Cancer

Volumn 32, Issue SUPPL. 4, 1996, Pages

  Vijgh, W J F van der ^a   Korst, A E C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

amifostine; animal; carboplatin; cisplatin; Ethyol ; patient; pharmacodynamics; pharmacokinetics; WR 1065; WR 2721

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN;

ANIMAL; DNA ADDUCT; DRUG ADMINISTRATION; DRUG EFFECT; DRUG INTERACTION; FEMALE; MOUSE; OVARY TUMOR; REVIEW;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DNA ADDUCTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; MICE; OVARIAN NEOPLASMS;

EID: 34547648771     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00332-2     Document Type: Article

References (21)

1. Cisplatin dose intensity
2. The mechanism of action of platinum antitumor drugs
3. The coordination chemistry of platinum anticancer drugs and related compounds with DNA
4. WR-2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach
5. Can WR-2721 be improved upon?
6. Pharmacokinetics of WR-2721
7. ®, amifostine) in the BALB/c mouse
8. A sensitive HPLC-ECD assay for amifostine and its metabolites in plasma
9. Measurement of S-2-(3-aminopropyl-amino) ethanethiol (WR-1065) in blood and tissue
10. Pharmacokinetics of amifostine in plasma and ascites of patients
11. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
12. Pharmacokinetics and disposition of WR-1065 in the rhesus monkey
13. Effects of the modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin—DNA adducts in vitro in comparison to the effects of thiosulfate and diethyldithiocarbamate
14. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse
15. Clinical pharmacokinetics of carboplatin
16. Influence of amifostine (AMI) on the pharmacokinetics (PK) of carboplatin (CARBO) in patients with solid tumors
17. Phase I study of WR-2721 and carboplatin
18. Effects of the modulating agent WR-2721 on myclotoxicity and antitumor activity in carboplatin-treated mice
19. Bone marrow protection by amifostine (AMI) in patients treated with carboplatin (Carbo): a phase I study
20. Influence of amifostine on the antitumor activity, pharmacokinetics and pharmacodynamics of carboplatin in nude mice
21. Biochemical modification of the toxicity and the anti-tumor effect of 5-fluorouracil and cis-platinum by WR-2721 in mice